ICU Medical (STU:IC7) Tariff Resilience Score: 6/10 (As of Aug. 17, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:IC7 ICU Medical Inc STU:IC7
80 GF Score
Price €158.00
GF Value €105.79
Valuation Significantly Overvalued
! 8 Warning Signs
View Full Analysis

What is ICU Medical Tariff Resilience Score?

ICU Medical STU:IC7 80 Tariff Resilience Score is 6 as of Aug. 17, 2026. GuruFocus rates STU:IC7 with a GF Score™ of 80/100 and a GF Value™ of €105.79 (Significantly Overvalued). The stock has 8 warning signs investors should review. Among 827 Medical Devices & Instruments companies, ICU Medical ranks better than 90.93% on this metric.

ICU Medical has the Tariff Resilience Score of 6, which implies that the company might have Average Resilient.

ICU Medical has ICU Medical Inc has a balanced import/export profile with manufacturing in multiple regions. The company has some pricing power and can mitigate tariff impacts through alternative suppliers. Historical tariff changes have had limited impact due to industry exemptions.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes ICU Medical might have Average Resilient.

ICU Medical  (STU:IC7) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

ICU Medical Tariff Resilience Score Related Terms

STU:IC7 vs NVST, MMSI, MMED: Tariff Resilience Score Comparison

For the Medical Instruments & Supplies subindustry, ICU Medical's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ICU Medical Tariff Resilience Score vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, ICU Medical's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where ICU Medical's Tariff Resilience Score falls into.


STU:IC7
80GF Score
ICU Medical Inc STU:IC7
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 6 mean?
ICU Medical (STU:IC7) has a Tariff Resilience Score of 6 as of Aug. 17, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, ICU Medical ranks #75 out of 827 companies in the Medical Devices & Instruments industry, placing it in the top 9.1%.
Is ICU Medical's Tariff Resilience Score too high?
ICU Medical's current Tariff Resilience Score is 6. Based on the distribution chart, ICU Medical ranks #75 out of 827 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, ICU Medical has a GF Score™ of 80/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does ICU Medical's Tariff Resilience Score compare to NVST and MMSI?
According to the Medical Devices & Instruments industry distribution chart, ICU Medical ranks #75 out of 827 companies for Tariff Resilience Score. This places ICU Medical in the top 9% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Medical Devices & Instruments company?
A good Tariff Resilience Score depends on the Medical Devices & Instruments industry context. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. ICU Medical's current Tariff Resilience Score is 6. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ICU Medical stock overvalued right now?
Based on GuruFocus' analysis, ICU Medical (STU:IC7) is currently considered Significantly Overvalued. The stock's GF Value™ is €105.79, compared to a current price of €158.00 — trading 49.4% above its estimated fair value. The current Tariff Resilience Score is 6. ICU Medical's overall GF Score™ is 80/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For ICU Medical (STU:IC7), the current Tariff Resilience Score is 6 as of Aug. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is ICU Medical (STU:IC7) Overvalued in 2026?

Based on GuruFocus' analysis, ICU Medical stock appears to be overvalued. The current stock price of €158.00 is trading 49.4% above its estimated GF Value™ of €105.79. GuruFocus considers ICU Medical to be Significantly Overvalued.

Key valuation signals for STU:IC7:

  • Tariff Resilience Score: 6
  • GF Value™: €105.79 vs. price of €158.00 (49.4% above fair value)
  • GF Score™: 80/100 with 8 warning signs

No single metric tells the full story. See the STU:IC7 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

ICU Medical Business Description

Other Exchanges ICUI:USA
Address 951 Calle Amanecer, San Clemente, CA, USA, 92673
ICU Medical is a California-based pure-play infusion therapy company that provides consumables, systems, and services for virtually every component of the IV continuum of care. ICU has become one of the largest players in its industry following its acquisition of Hospira Infusion Systems from Pfizer in 2017 and Smiths Medical from Smiths Group in 2022. It holds top-tier positions across its three reporting segments: consumables (50% of consolidated revenue), infusion systems (30%), and vital care (20%). The combined entity remains primarily US-focused, generating over 60% of its sales domestically.
80GF Score

Get the complete analysis for STU:IC7

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€158.00
Price
€105.79
GF Value